Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women

详细信息    查看全文

• 作者：James P. Carroll (1) (5)
  Melinda M. Protani (1) (2)
  Linda Nguyen (1)
  Matthew E. Cheng (1)
  Mike Fay (1) (7)
  Mohamed Saleem (6)
  Praga S. Pillay (1) (8)
  Euan Walpole (1) (3)
  Jennifer H. Martin (1) (4)
  
• 关键词：Anti ; neoplastic ; Breast ; Chemotherapy ; Obesity ; Toxicity
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：31
• 期：4
• 全文大小：235 KB
• 作者单位：James P. Carroll (1) (5)
  Melinda M. Protani (1) (2)
  Linda Nguyen (1)
  Matthew E. Cheng (1)
  Mike Fay (1) (7)
  Mohamed Saleem (6)
  Praga S. Pillay (1) (8)
  Euan Walpole (1) (3)
  Jennifer H. Martin (1) (4)
  
  1. School of Medicine, University of Queensland, Herston Road, Herston, Brisbane, QLD, Australia
  5. Division of Surgery, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, Brisbane, QLD, 4102, Australia
  2. School of Population Health, University of Queensland, Herston Road, Herston, Brisbane, QLD, 4006, Australia
  7. Division of Oncology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
  6. SA Pathology, Adelaide, SA, Australia
  8. Division of Surgery, QE II Jubilee Hospital, Brisbane, QLD, Australia
  3. Division of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD, Australia
  4. Division of Internal Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD, Australia
  
• ISSN：1559-131X

文摘

The purpose of this study was to compare toxicity rates and types between obese and non-obese women during adjuvant chemotherapy for breast cancer, adjusting for regimen type and received dose. We conducted a retrospective cohort study of 537 women receiving chemotherapy, initially treated between 2007 and 2010 at two tertiary hospitals in Brisbane, Australia. Demographic, chemotherapy and toxicity data were extracted from patient charts and analyzed using multivariate logistic regression. Three hundred and seventy-four women were eligible for inclusion. Obese women (body mass index (BMI)?>?30?kg/m2; mean age 52.58?±?9.49) were older than non-obese women (BMI?≤?9.9?kg/m2; mean age 50.19?±?11.15, P?=?0.05) and had more comorbidities (P?<?0.01). After adjustment for potential confounders, obesity was not statistically related to chemotherapy-related admission risk (OR 1.27; 95?% CI 0.78-.09) or febrile neutropenia risk (OR 0.56; 95?% CI 0.28-.21). However, obese women received chemotherapy with proportionally lower mean relative dose intensity than non-obese women (94 vs. 97?% of reference dose, P?=?0.03). Eighteen (15.8?%) obese and zero non-obese women (P?<?0.01) had their chemotherapy dose capped at an arbitrary body surface area. Compared with non-obese women, obese women receive different chemotherapy regimens and relatively lower chemotherapy doses. There was no significant evidence of increased toxicity among obese women with either full or adjusted chemotherapy doses. Full body surface areas-based dosing appears to be tolerated as well in obese as in lean women.